That got me to thinking about Leronlimab-PLS and w
Post# of 153278

"Yes, the FcRn-enhancing mutations used in Leronlimab-PLS could potentially aid blood-brain barrier (BBB) transit. Research has shown that modifying antibody-FcRn interactions can enhance IgG transport across the BBB, improving brain penetration2.
FcRn is highly expressed at the BBB, meaning engineered antibodies can leverage receptor-mediated transcytosis to cross into the brain."

